nach oben

Erschienen in:

03.06.2017 | General Gynecology

Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue

verfasst von: Vanessa Toderow, Martina Rahmeh, Simone Hofmann, Verena Kirn, Sven Mahner, Udo Jeschke, Viktoria von Schönfeldt

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The nuclear hormone receptor estrogen receptor α (ERα) is pivotal for numerous processes in the cell. As a transcription factor, it regulates eukaryotic gene expression and affects cellular proliferation and differentiation in target tissues. Moreover, ERα is known for its influence on various gynecological diseases and carcinogenesis. Since its expression is often altered in diseased tissues and this alteration was found to be caused by hypermethylation of the ESR1 promotor region in cancer, including breast and colorectal cancer, the aim of this study is to elucidate if the expression of ERα is also regulated epigenetically in endometriosis and endometrial cancer.

Methods

Using real-time methylation-specific PCR (rt-MSP), we examined endometrial and endometriotic tissues as well as five endometrial cancer cell lines and compared the methylation status with the actual expression of ERα.

Results

The results of our study indicate that, though its expression is altered in endometrial and endometriotic tissue, ERα is not regulated by methylation of the promotor region in endometriosis. In contrast, three of the five endometrial cancer cell lines are methylated in the promotor region of ESR1.

Conclusions

Thus, further investigation of the connection between ERα and endometrial cancer will be the next step.

Ali SH, O’donnell AL, Mohamed S et al (2004) Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: inhibition of growth and angiogenic factors. Gynecol Oncol 95:637–645CrossRefPubMed

Berger U, Mcclelland RA, Wilson P et al (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Can Res 51:239–244

Bloski T, Pierson R (2008) Endometriosis and chronic pelvic pain: unraveling the mystery behind this complex condition. Nurs Women’s Health 12:382–395CrossRef

Bopp B, Shoupe D (1993) Luteal phase defects. J Reprod Med 38:348–356PubMed

Cunha-Filho JS, Gross JL, Bastos De Souza CA et al (2003) Physiopathological aspects of corpus luteum defect in infertile patients with mild/minimal endometriosis. J Assist Reprod Genet 20:117–121CrossRefPubMedPubMedCentral

Eads CA, Lord RV, Kurumboor SK et al (2000) Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Can Res 60:5021–5026

Eeckhoute J, Keeton EK, Lupien M et al (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Can Res 67:6477–6483CrossRef

Elledge RM, Green S, Pugh R et al (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111–117CrossRefPubMed

Engemise SL, Willets JM, Taylor AH et al (2011) Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol 157:101–106CrossRefPubMed

10.

Esteller M, Corn PG, Baylin SB et al (2001) A gene hypermethylation profile of human cancer. Can Res 61:3225–3229

11.

Harder J, Engelstaedter V, Usadel H et al (2009) CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer 100:360–365CrossRefPubMedPubMedCentral

12.

Holmes KA, Song JS, Liu XS et al (2008) Nk3–1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Can Res 68:7380–7385CrossRef

13.

Holst F, Hoivik EA, Gibson WJ et al (2016) Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep 6:25521CrossRefPubMedPubMedCentral

14.

Hua S, Kittler R, White KP (2009) Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137:1259–1271CrossRefPubMedPubMedCentral

15.

Hurtado A, Holmes KA, Geistlinger TR et al (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–666CrossRefPubMedPubMedCentral

16.

Issa JP, Ottaviano YL, Celano P et al (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7:536–540CrossRefPubMed

17.

Issa JP, Zehnbauer BA, Civin CI et al (1996) The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Can Res 56:973–977

18.

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed

19.

Jongen V, Briet J, De Jong R et al (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112:537–542CrossRefPubMed

20.

Kanwal R, Gupta S (2012) Epigenetic modifications in cancer. Clin Genet 81:303–311CrossRefPubMed

21.

Kokka F, Brockbank E, Oram D et al (2010) Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD007926.pub2

22.

Lapidus RG, Ferguson AT, Ottaviano YL et al (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res Off J Am Assoc Cancer Res 2:805–810

23.

Lapidus RG, Nass SJ, Butash KA et al (1998) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Can Res 58:2515–2519

24.

Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mamm Gland Biol Neoplasia 3:85–94CrossRef

25.

Li Q, Seo JH, Stranger B et al (2013) Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152:633–641CrossRefPubMedPubMedCentral

26.

Liu X, Shi H (2015) Regulation of estrogen receptor α expression in the hypothalamus by sex steroids: implication in the regulation of energy homeostasis. Int J Endocrinol 2015:949085PubMedPubMedCentral

27.

Matorras R, Rodriguez F, Perez C et al (1996) Infertile women with and without endometriosis: a case control study of luteal phase and other infertility conditions. Acta Obstet Gynecol Scand 75:826–831CrossRefPubMed

28.

Moeloek FA, Moegny E (1993) Endometriosis and luteal phase defect. Asia Ocean J Obstetr Gynaecol 19:171–176CrossRef

29.

Pandya KJ, Yeap BY, Weiner LM et al (2001) Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 24:43–46CrossRefPubMed

30.

Rendina GM, Donadio C, Fabri M et al (1984) Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 17:285–291CrossRefPubMed

31.

Rogers PA, D’hooghe TM, Fazleabas A et al (2009) Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci (Thousand Oaks, Calif) 16:335–346CrossRef

32.

Ross-Innes CS, Stark R, Holmes KA et al (2010) Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 24:171–182CrossRefPubMedPubMedCentral

33.

Thigpen T, Brady MF, Homesley HD et al (2001) Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19:364–367CrossRefPubMed

34.

Yue W, Yager JD, Wang JP et al (2013) Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 78:161–170CrossRefPubMed

Titel: Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue
verfasst von: Vanessa Toderow
Martina Rahmeh
Simone Hofmann
Verena Kirn
Sven Mahner
Udo Jeschke
Viktoria von Schönfeldt
Publikationsdatum: 03.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2017
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4405-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Patient-completed or symptom-based screening tools for endometriosis: a scoping review

The impact of postpartum cervical tear on the occurrence of preterm birth in subsequent pregnancy

Gynecologic oncologists’ attitudes and practices relating to integrative medicine: results of a nationwide AGO survey

Mifepristone vs balloon catheter for labor induction in previous cesarean: a randomized controlled trial

Compartment syndrome after gynecologic laparoscopy: systematic review of the literature and establishment of normal values for postoperative serum creatine kinase and myoglobin levels

Three studies in the focus of pelvic organ prolapse research

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie